A long-term surviving patient with recurrent low-grade serous ovarian carcinoma treated with the MEK1/2 inhibitor, selumetinib.

Gynecol Oncol Res Pract · 2016 · PMC4880811 · PMID 27231576

Europe PMC DOI

hedged sentence

0.6300

closest p · 12.6× alpha

0.6300

boldest claim

The sentences

did not reach statistical significancep = 0.63not close (p > 0.1)

published an analysis of 58 patients with recurrent LGSOC in which the overall response rate was 3.7 %; dividing the regimens by platinum-status, the response rate was 4.9 % in platinum-sensitive tumors and 2.1 % in platinum-resistant tumors, but that difference did not reach statistical significance ( p = 0.63) [ 3 ].

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.